Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gapping up...for the record...
In reaction to strong earnings/guidance: SANW +13.3%, QKLS +9.7%, EMAN +8.7%, UPLD +8.2%, ISNS +5.2%, ONTX +5.1%, SINA +1.4%, GLOB +1.3%, ENSV +0.6%, AMGN +0.5%, HOLI +0.5%
M&A news: BAGR +13% (Diversified Restaurant Holdings to acquire eighteen Buffalo Wild Wings restaurants (BWLD) for $54 mln), SZMK +5.1% (acquires mobile advertising demand side platform, StrikeAd; co also reported earnings)[sic]
Other news: DRWI +12.2% (announced it has signed a supply agreement for DragonWave microwave radio systems and related services with a leading Indian telecommunications company), TCON +10.6% ( announces that TRC105 has received FDA fast track designation), PTX +8.4% (announces FDA approval for TREXIMET, to treat pediatric patients with acute migraines), UPLD +8.2% (announced $60 mln credit facility for acquisitions; co also reported earnings), ESI +5.5% (discloses confirmation of SEC complaint against it and various of its officers, issues further response), BDSI +4.9% (BioDelivery Sciences and Endo Pharma (ENDP) present pivotal data from two Phase 3 trials demonstrating safety and efficacy of Buprenorphine HCl Buccal Film; Statistically significant percentage of patients on BEMA buprenorphine experienced pain reductions of greater than 30% vs placebo ), YOKU +4.6% (cont strength), NRZ +4.1% (increased quarterly dividend to $0.45/share from $0.38/share), FRO +3.9% (still checking), AMCC +2.7% (Kingdom Ridge Capital discloses 9.85% active stake in 13D filing; Christopher Zepf to join Board), NFLX +2.5% (WSJ details news that Netflix is in discusses to bring content to China), GLUU +1.9% (rebounding following yday's decline), SSE +1.5% (announced entrance into $100 mln in junior lien financing under its term loan facility with BlueMeridian Capital), SHPG +1.5% (cont strength), MOS +1.4% (announces authorization for a new $1.5 billion share repurchase program, and increases its quarterly dividend to $0.275 from $0.25/share ), EBAY +1.1% (eBay names Board of Directors for eBay and PayPal following separation), HMHC +1% (prices 10,575,300 shares of its common stock at $23.00 per share; shares offered by selling shareholders), OIBR +1% (issues response to reports it has retained Credit Suisse to sell its call centers, which employ 11% of its entire workforce), RMD +1% (agreed to sell mute snoring and sleep technology online)
Analyst comments: ADXS +5.7% (initiated with a Buy at Janney and Jefferies), MT +3% (upgraded to Buy at BofA/Merrill), INOV +2.6% (upgraded to Buy from Neutral at Goldman), DEG +2.1% (upgraded to Buy at Rabobank), UPS +1% (upgraded to Buy from Neutral at Goldman), YUM +0.9% (upgraded to Overweight from Neutral at JP Morgan)
Read more: http://www.briefing.com/GeneralContent/Platinum/Active/FullTextSearch/FullTextSearch.aspx#ixzz3aDTprFb0
edit: a 32 cent spread...cricky...CLVS did a gap and trap today...nice short so far...no position here...
Just got my very own "IRS is filing suit against you" phone call.
These scams are apparently not at all new...but somehow it still gives me that sucky feeling in my stomach...lol
https://www.consumer.ftc.gov/blog/my-very-own-irs-imposter-call
Thanks for the ANDE mention, stuffit...this is all I found on it...the usual maybe, but maybe not...
:)
Notable movers of interest
The following are some of today's most notable movers of interest, categorized by market capitalization (large cap over $10 billion and mid cap between $2-10 billion) and ranked by % change (all stocks over 100K average daily volume).
Large Cap Gainers
NTES (142.33 +9.48%): Reported Q1 (Mar) earnings of $1.55 per share, $0.06 better than the Capital IQ Consensus Estimate of $1.49; revenues rose 55.5% year/year to $590.46 mln vs the $506.67 mln consensus.
MT (11.57 +5.66%): Outperforming on reports of EC steel anti-dumping duties.
IR (69.78 +2.44%): Upgraded to Overweight at Keybanc Capital Mkts.
Large Cap Losers
KSS (65.62 -11.93%): Reported Q1 (Apr) earnings of $0.63 per share, $0.08 better than the Capital IQ Consensus Estimate of $0.55; revenues rose 1.3% year/year to $4.12 bln vs the $4.19 bln consensus; Comps +1.4% vs. +2.5% estimates.
HOG (54.1 -3.05%): Under pressure following cautious comments from ITG.
KSU (95.24 -1.93%): Withdrew 2015 rev and volume guidance; Q2 volume -7% as coal, energy remain weak.
Mid Cap Gainers
CTRP (72.5 +10.92%): Beat Q1 consensus EPS estimates by $0.13, beat on revs; guided for Q2 rev growth of 45-50%; Upgraded at Stifel and Oppenheimer.
MIDD (108.89 +7.16%): Reported Q1 (Mar) earnings of $0.80 per share, excluding non-recurring items, $0.09 better than the Capital IQ Consensus Estimate of $0.71; revenues rose 9.2% year/year to $406.6 mln vs the $413.76 mln consensus.
PBH (44.34 +6.46%): Beat Q4 (Mar) consensus EPS estimates by $0.02, beat on revs; guided FY16 EPS in-line, revs in-line.
Mid Cap Losers
PBYI (171.91 -18.03%): Announced publication of four abstracts for presentation at ASCO; treatment effect of PB272 (neratinib) was smaller than expected.
VSTO (42.43 -3.44%): Reported Q4 (Mar) earnings of $0.47 per share vs $0.58 Capital IQ consensus. revs fell 14% YoY to $485 mln vs $488.02 mln Capital IQ consensus; guided for FY16 EPS below consensus; revs in line.
OMAM (18.96 -3.63%): Beat Q1 consensus EPS estimates by $0.01, reported revs in-line; AUM of $224.0 billion at March 31, 2015, up 10% from March 31, 2014.
CLVS...WOW on today's candle...96.83, up 13% today...get used to this stuff going on...ASCO is coming up soon...
Today's biggest point gainers/losers
Biggest point gainers:
CTRP (74.22 +8.86), NTES (137.79 +7.79), GOOGL (545.99 +6.50), GLPG (47.70 +5.65), GOOG (535.16 +5.54), MCK (237.13 +4.75), SHAK (72.73 +4.37), AMZN (430.35 +3.48), TQQQ (112.45 +3.37), CMCM (29.83 +3.00), TSO (91.74 +2.94), QUNR (49.57 +2.85), QIWI (32.71 +2.83), FB (80.86 +2.42), BA (148.00 +2.38), CLVS (88.37 +2.37), UNH (118.20 +2.34), AMGN (160.72 +2.33), AAPL (128.30 +2.29), DEO (112.60 +2.25), PBH (43.88 +2.23), ASH (127.83 +2.20), LMT (193.16 +2.16), PANW (153.62 +2.14), MPC (104.29 +2.01)
Biggest point losers:
PBYI (170.38 -39.34), KSS (66.07 -8.44), JACK (88.09 -3.69), TGT (76.59 -3.22), NHTC (28.02 -2.88), MMYT (20.53 -2.72), VRTX (122.85 -2.67), DGLY (15.65 -2.65), DDS (123.93 -2.62), GWRE (49.31 -2.54), SIG (132.78 -2.45), HOG (53.52 -2.28), KSU (95.22 -1.89), MDVN (120.83 -1.82), ROST (99.46 -1.78), VSTO (42.19 -1.75), CXO (116.38 -1.69), FMI (37.52 -1.65), FGEN (22.02 -1.58), NLNK (36.72 -1.57), KPTI (27.80 -1.54), TIF (85.43 -1.51), FEYE (42.09 -1.37), KITE (53.77 -1.34), LNKD (195.53 -1.34)
Gapping down
In reaction to disappointing earnings/guidance: MBLX -30.8%, HIIQ -19.4%, DGLY -17.5%, INVE -13.5%, ANY -13.4%, KSS -10.7%, DARA -5.6%, CADC -4.5%, HIMX -4.1%, LXFT -4%, VOXX -3.8%, VSTO -2.1%, CEL -1.7%, CSCO -0.9%, BGMD -0.7%, HSGX -0.6%
Other news: PBYI -17.9% (co announced publication of four abstracts for presentation at ASCO; treatment effect of PB272 (neratinib) was smaller than expected), ANY -13.4% (signed definitive agreements for a private placement of 1,281,250 Common Shares and Warrants to purchase up to 1,281,250 Common Shares for a gross purchase price of ~$4.1 mln), CAMT -11.2% (is offering to sell its ordinary shares in an underwritten public offering), JONE -10.7% ( launches secondary offering of 5 mln Class A common stock by selling stockholders ), GEVO -8.9% (prices its offering of 4.3 mln common stock units at $4/unit- which includes one common stock share and one Series C warrant), CLSN -7.1% (announced results from its Phase Ib trial for GEN-1 in platinum-resistant ovarian cancer will be presented at the ASCO annual meeting; findings demonstrated an overall clinical benefit of 57% for all treatment arms), NVIV -4.5% (announces an update on initial patients implanted with its Neuro-Spinal Scaffold), OHGI -4.2% (following 100%+ move yesterday), FEYE -2.8% (Cisco CEO downplayed rumors that co may acquire FEYE), BIOC -2.1% (filed for $50 mln mixed securities shelf offering), SD -2% (disclosed exchange agreement with an existing holder), Q -1.1% (priced its 11.86 mln share secondary offering of common stock by existing shareholders at $65.00 per share)
Analyst comments: BMY -2.4% (initiated with a Hold at Berenberg), GSK 1.1% (downgraded to Neutral at UBS)
Read more: http://www.briefing.com/Platinum/InDepth/InPlay.htm#ixzz3a7IsT784
Gapping up
In reaction to strong earnings/guidance: RGDX +18.8%, PGN +16.6%, PERY +16.4%, CTRP +13.9%, SHAK +6.8%, NTES +4.7%, MXPT +4%, TGB +3.6%, YOD +3.2%, EYES +2.8%, VIPS +1.8%, MSLI +1.7%, TNK +1.5%, CAAS +1.4%, STOR +1.2%, BCLI +1.1%, TCON +1.1%, JD +0.7%, JACK +0.6%, MORE +0.6%, VWR +0.6%
M&A news: ISSI +6.9% (Cypress Semiconductor (CY) sent letter to the Board of Integrated Silicon Solution offering to acquire 100% of its outstanding shares of common stock for $19.75 per share in cash), CY +2.8% (Sends Letter To Board Of Directors Of Integrated Silicon Solution, offers to purchase ISSI for $19.75 per share )
Select metals/mining stocks trading higher: MT +6.9%, AKS +2.8%, NOR +2.3%, X +2%, CLF +1.9%, SLV +1.5%, GOLD +1.1%, SLW +1%, AG +1%
Other news: CYRN +19.3% (agreement with Dell that adds CYREN's antimalware technology to Dell SonicWALL Email Security appliances, software, virtual appliances and hosted services), ACRX +19.3% (discloses entry into an award contract supported by the United States Army Medical Research and Materiel Command), ONTY +15.5% (Two abstracts related to ONT-380 for the treatment of breast cancer published), VBLT +11% (to present positive Phase 1/2 data for VB-111 in recurrent platinum-resistant Mullerian cancer at ASCO), WLT +9.6% (disclosed that on May 7, 2015, Brian M. Chopin, Assistant Corporate Controller was appointed Acting Corporate Controller and Chief Accounting Officer, effective May 20, 2015), DSCO +9.6% (reports top line data from its AEROSURF Phase 2a clinical trial), NVGN +5.9% (announces that it has confirmed that drug candidate, Anisina, is an effective monotherapy against human melanoma in an animal model), QIWI +4.4% (announces entrance into an agreement with Otkritie Financial Group to acquire its Contact money transfer and Rapida payment processing systems ), NOG +4.3% (priced its private offering of $200 mln in 8% senior notes due 2020 at 95% of par), TGTX +3.6% (announced clinical data presentations at ASCO; shares up ~3.6% in after hours trade), NBG +3.6% (optimistc tone from Greece Fin Min in comments today), MNKD +3.3% (still checking), SAM +2.1% (increases limit for stock repurchase program by additional $50 mln, bringing total limit to $400 million ), SAM +2.1% (increased limit for stock repurchase program by additional $50 mln, bringing total limit to $400 million), REN +2.1% (cont strength), STM +1.9% (CY/ISSI peer), SHPG +1.8% (still checking), NICE +1.7% (cont strength), INFN +1.6% (CY/ISSI peer), ASML +1.4% (CY/ISSI peer), SGMO +1.3% (will consolidate development plans for its zinc finger nuclease-mediated genome editing programs ) COWN +1.1% (prices offering of $105 million of shares of 5.625% Series A Cumulative Perpetual Convertible Preferred Stock), SPB +0.9% (priced 5,405,405 shares of common stock $92.50 per share)
Analyst comments: AKBA +5.1% (initiated with a Buy at Brean Capital), TSEM +4.5% (target raised to $28 from $24 at Ascendiant Capital Markets; also announced they have collaborated w UCSB to demonstrate the first 256-element), CWST +3.5% (upgraded to Outperform from Mkt Perform at Raymond James), ATML +2.7% (upgraded to Overweight from Equal Weight at a boutique firm), EURN +2.3% (initiated with a Outperform at Credit Suisse), KATE +1.7% (initiated with a Outperform at Wedbush), LLTC +1.6% (upgraded to Neutral from Underweight at JP Morgan), KMX +1.1% (initiated with a Buy at Sterne Agee CRT), DD +1% (upgraded to Neutral from Underperform at BofA/Merrill)
Read more: http://www.briefing.com/Platinum/InDepth/InPlay.htm#ixzz3a7H14Zfe
Nice day...first day to trade in a while w/o distractions from repairmen, plumbers, and lawn guys....
Be back tomorrow...have a good evening, all...
CSCO is trading not far off the close...quite a bit can happen overnight...
so far, so good, methinks...thanks for posting your pick...always makes it moe interesting...
Nice catch...sweet trade...
Exited UNP with a few cents profit and called it a day...
will watch tomorrow, but this stock will be news dependent on talk of the 'crude-by-rail' safety rules...
Thanks! Yeah...good thing we don't have anybody here with delicate sensibilities...I'd have to change my entire trading lingo...lol
Notable movers of interest
The following are some of today's most notable movers of interest, categorized by market capitalization (large cap over $10 billion and mid cap between $2-10 billion) and ranked by % change (all stocks over 100K average daily volume).
Large Cap Gainers
WPZ (56.96 +20.17%): To be acquired by Williams (WMB) in a $13.8 bln deal, combined entity is expected to generate adjusted EBITDA of ~$5.4 bln in 2016.
PLL (124 +4.54%): To be acquired by Danaher (DHR) for $127.20 per share in cash, or $13.8 bln including assumed debt and net of acquired cash.
ABX (13.27 +3.4%): Outperforming on the heels of strength in Gold futures as the precious metal jumps $23 to $1216/ozt; separately reports out that it and Glencore (GLNCY) are considering sale of a nickel project in Tanzania.
Large Cap Losers
DD (69.72 -6.25%): Preliminary results indicate shareholders have elected all 12 DuPont director nominees, choosing not to elect any Trian nominee.
RL (129.71 -2.62%): Beat Q4 (Mar) consensus EPS estimates by $0.10, reported revs in-line; authorized an additional $500 mln stock repurchase, expects consolidated net revenues to be flat in Q1 of FY16.
ECA (13.51 -2.56%): Downgraded to Sector Perform from Outperform at RBC Capital Mkts; tgt raised to $15.
Mid Cap Gainers
ZBRA (102.83 +9.79%): Beat Q1 consensus EPS estimates by $0.28, beat on revs; guided Q2 in-line.
OI (26.22 +10.21%): Announced it would acquire Vitro S.A.B's food and beverage business for $2.15 bln, with expected accretion to cash flow and EPS in 2016.
CALM (53.46 +4.54%): Continued strength following additional reports of the spread of the bird flu throughout the U.S.; Post (POST) announced that chicken flocks at its owned and third party farms in Nebraska and Iowa tested positive for avian influenza; estimates that ~20% of egg supply has been affected.
Mid Cap Losers
RMD (55.42 -15.22%): Provided an update on its Phase III SERVE-HF Study of Adaptive Servo-Ventilation Therapy In central sleep apnea and chronic heart failure; the study did not meet primary endpoint; downgraded to Neutral from Buy at BofA/Merrill.
RICE (23.5 -6.45%): Announced and priced an offering of 6 mln shares of common stock by a selling stockholder at $24.20 per share.
ZAYO (26.29 -6.17%): Reported Q3 (Mar) loss of $0.22 per share, includes items, may not be comparable to the Capital IQ Consensus Estimate of $0.04; revenues rose 21.1% year/year to $340.7 mln vs the $333.4 mln consensus.
Yep...tried to catch UNP and it is about to stop me out..
Tough game we play...
Mostly I like to be in for the fall, not for the bounce...lol
Today's biggest point gainers/losers
Biggest point gainers:
ZBRA (105.43 +11.77), RENT (61.31 +10.20), WPZ (57.56 +10.16), MCK (235.24 +5.69), PLL (124.23 +5.61), VRTX (128.38 +4.30), OCR (91.94 +3.27), GOLD (76.67 +2.67), WMB (52.75 +2.65), MLM (153.38 +2.63), GOOGL (540.99 +2.26), CALM (53.38 +2.24), GOOG (531.27 +2.23), OI (26.01 +2.22), HON (104.47 +2.16), USLV (21.73 +2.04), OKS (39.94 +1.92), ROK (123.47 +1.81), GMCR (102.06 +1.80), MON (117.81 +1.75), IBM (172.30 +1.75), PPO (59.49 +1.65), DHR (87.61 +1.61), NLNK (38.12 +1.57), BABA (88.32 +1.55)
Biggest point losers:
RMD (55.47 -9.90), GWW (244.89 -6.35), BLUE (161.13 -5.08), EZCH (14.79 -4.78), DD (69.94 -4.42), CP (178.39 -4.32), BIIB (391.28 -4.02), UNP (102.03 -3.74), IFF (110.82 -3.58), POST (45.50 -3.41), RL (129.89 -3.31), HAR (127.38 -2.91), ACAT (32.44 -2.63), Z (95.43 -2.55), PII (140.09 -2.24), FOSL (77.24 -2.13), MNST (129.80 -2.12), PCRX (73.42 -2.08), AMZN (429.10 -1.92), CXO (117.68 -1.91), VRX (221.06 -1.90), CNI (61.84 -1.88), EQT (90.07 -1.85), RAX (44.13 -1.83), PXD (152.73 -1.81)
Read more: http://www.briefing.com/Platinum/InDepth/InPlay.htm#ixzz3a2DgmvUc
Check your 5 min charts...UNP down...and MOS and POT are up right now...
OC is coming in and may break down...also M behaving just like RL...so far...
RAX on day 2 of the gap down is falling off a cliff...
I thought it would happen yesterday, but it waited...
Charts and comments are one click back...
RL closed the gap, and is now trekking right back down...which was the original direction in premarket...
Plenty of folks bought the dip first thing this morning...now they may be trapped...
RL gapped open down big...then bullied right up to fill the gap...
Managed to get a very few shares on the puke-out at 130.59, and sold at 133.00...whew
Really faster than I like, but puke-out plays require very little finesse when you find them...and they are so quick, no patience is required either...lol
Gapping down
In reaction to disappointing earnings/guidance: EZCH -23% (also EZchip's NPS-400 is currently not the plan of record for customer's Cisco (CSCO) next generation line cards), VSLR -8.2%, EXAR -6.9%, NLST -6.7%, INFU -4.7%, ELMD -4.2%, LMNS -3.1%, GDDY -2.7%, PRSS -2.6%, M -2.5%, VUZI -2.1%, AEG -2%, RL -0.9%
Other news: OREX -10.6% (Takeda is now claiming breach of contract; provides statement on termination of the light study and updates on Contrave collaboration with Takeda Pharmaceuticals), SBLK -7.2% (announces $150.0 million public offering of common shares), LAND -5.6% (announced that it plans to sell ~1.1 mln shares of common stock ), CRDS -4.1% (announced a planned rights offering of common stock, to common and preferred shareholders; size not disclosed), RICE -3.7% (prices 6,000,000 shares of its common stock owned by NGP Rice Holdings at $24.20 per share of common stock), AES -1.6% (announced a 60 mln share secondary common stock offering, by selling stockholder Terrific Investment Corporation), PGH -1.3% ( confirms the filing of a preliminary base shelf prospectus for up to $1 bln in securities )
Analyst comments: VALE -0.9% (downgraded to Neutral from Outperform at Macquarie)
Read more: http://www.briefing.com/Platinum/InDepth/InPlay.htm#ixzz3a1QZ5iV3
Gapping up
In reaction to strong earnings/guidance: PDII +16.5%, GEVO +16%, TUBE +14.6%, HDP +11.7%, SYMX +10.9%, OPWR +10.3%, BIOC +7%, RENT +6.6%, ICCC +5.7%, CARA +5.6%, NVFY +5.5%, NEWR +5.3%, NVMI +4.7%, TSEM +4.6%, VIP +4.5%, ZBRA +3%, STKL +2.8%, ICL +2.3%, HCKT +1.9%, ELOS +1.9%, SSRI +1.8%, NAII +1.5%, MNGA +1.2%, VJET +1%, PCP +1%
M&A news: WPZ +26.1% (Williams (WMB) to acquire all public equity of Williams Partners L.P.), OI +8.4% (acquires Vitro S.A.B's food and beverage business for $2.15 bln), WMB +8.4% (Williams (WMB) to acquire all public equity of Williams Partners L.P.), WX +5.9% (forms special committee of independent directors to evaluate the previously announced proposed takeover transaction), DHR +5.8% (acquires PLL; Danaher announces intention to separate into two independent, publicly traded companies), PLL +4.9% (to be acquired by Danaher (DHR) for $127.20 per share), SPKE +1.9% (announces acquisition of Oasis Energy)
Select oil/gas related names showing strength: STKL +2.8%, SDRL +2%, SD +1.3%, TOT +1.3%, BP +0.9%.
Other news: FCSC +25.8% ( recieves rare pediatric disease designation for FCX-007 from the FDA, to treat recessive dystrophic epidermolysis bullosa), AMCF +8.7% (announced that its previously scheduled NASDAQ listing hearing was cancelled after co pays outstanding fees; announced business updates, including entery into a non-binding letter of intent with Three Pillars PetroChem), MAGS +7.3% (recieves two new orders, worth a total of $13 mln), VRTX +7.2% (confirmed FDA Advisory Panel voted 12 to 1 to recommend approval of ORKAMBI to treat people with cystic fibrosis ages 12 and older), NBG +5.1% (optimism with Greece situation), QSR +3.2% (announces an $1.2 bln offering of first lien senior secured notes due 2022), DAL +2.7% (announces a new $5 billion share repurchase program, and a dividend increase of 50% to $0.135/share beginning in the September, 2015 quarter), NRF +2% (still checking), PPO +2% (disclosed that at a special meeting, its stockholders approved the proposal to adopt the Agreement and Plan of Merger with Asahi Kasei), AXP +1.5% (authorizes repurchase of up to 150 mln shares, announces 12% dividend increase), JBLU +1.2% (reports its preliminary traffic results for April 2015), DEO +1% (peer SAB Miller reported bte results), SNY +1% (exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease under the terms of an existing strategic global collaboration with Selecta Biosciences), TASR +1% (announces recent multiple orders, including up to 460 X2 Smart Weapons for the Scottsdale Police Department, received and shipped in Q2)
Analyst comments: SSE +4.7% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey; tgt raised to $7 from $4), DRD +3.8% (upgraded to Overweight from Neutral at JP Morgan), GFI +1.9% (upgraded to Neutral from Sell at UBS), AEO +1.7% (upgraded to Outperform from Market Perform at Cowen), MSFT +1.4% (upgraded to Buy from Hold at Deutsche Bank), POWR +1.4% (upgraded to Buy at Maxim), KMB +0.9% (upgraded to Overweight from Equal Weight at Barclays)
Read more: http://www.briefing.com/Platinum/InDepth/InPlay.htm#ixzz3a1QF4gWN
NLNK, just a chrt idea...it is a biotech whose Phase 3 study re: pancreatic cancer was continued unmodified. Many had hoped for and planned on better news than that...
It would be possible to do DD until the world looks level on this one, but I am only posting because of the chart.
Void below it looks good for more downside (maybe to 32.50), even though the price is sitting on the 200sma right now...
Just one to watch for second day gyrations...but only if the volume is good again tomorrow...
Thanks for the insight...I do remember all that EBIX mess...
Totally agree...and the so-called bounce so far is not getting off the ground...may even be more downside in it...
Not in, and, like you...if it doesn't act right to me, I will not mess with it...
Thanks for the heads up, jj...
although I am sorry for your loss..
Heckuva red candle...will watch for a bounce,
but a scary dude...so, I may or may not play it...
Gapping down
In reaction to disappointing earnings/guidance: RARE -19.7%, LPSN -15.1%, RAX -14.5%, ATHX -13.7%, DEPO -10.7%, CLNE -9.5%, MTZ -7.6%, YY -7.5%, IPXL -7%, UNIS -6.6%, PAH -5.4%, AKAO -5.2%, ARWR -4.5%, LDR -3.9%, PBYI -3.5%, OME -3.4%, GPS -3.4%, JOBS -3.3%, CDTI -3.3%, JGW -2.9%, PVA -2.9%, OPK -2.9%, CRCM -2.8%, XONE -2.7%, PME -2.7%, HALO -2.4%, EGRX -2.3%, ZGNX -2.2%, KMDA -2%, UNXL -1.7%, DRNA -1.6%, MR -1.1%, MBI -1.1%, TWER -1.1%, TEP -1%, GBDC -0.9%, FXEN -0.9%, ACM -0.8%, STRI -0.8%, IMOS -0.7%, APP -0.5%
M&A news: VZ -0.9% (acquired by AOL for $50 per share, or ~$4.4 bln)
Select Airline related names showing weakness: DAL -1.3%, ALK -4.3%, TAL -1.9%, UAL -1.5%, LUV -1.1%.
Other news: NOR -23% ( announces a 22.84 mln share, secondary common stock offering, by selling stockholders affiliated with Apollo Global Management ), NLNK -20.5% ( IMPRESS Phase 3 pancreatic cancer trial with Algenpantucel-L to continue following second interim analysis ), MTZ -7.6% (discloses a delay in filing its Form 10-Q), IPXL -7% ( FDA performs GMP and pre-approval inspections of co's Hayward Facility), CBPX -6% (announces a secondary offering of 4.6 mln common stock shares by selling stockholders, which the co intends to purchase for ~$20 mln), XONE -2.7% (reported a delay in filing its form 10-Q for Quarter ending March, 2015), LL -2.6% (CNBC details news some Lumber Liquiditors (LL) insurers do not want to defend company in lawsuits), PUK -2.3% (announces that Pierre-Olivier Bouée is to step down as Group Chief Risk Officer), NBG -1.4% (EU mkts lower today, cont uncertainty with Greece default)
Analyst comments: SFUN -3.7% (downgraded to Hold from Buy at Deutsche Bank), I -2.4% (downgraded to Underweight from Equal-Weight at Morgan Stanley), POR -1.5% (downgraded to Neutral from Overweight at JP Morgan), MELI -1.1% (downgraded to Hold at Stifel)
Read more: http://www.briefing.com/Platinum/InDepth/InPlay.htm#ixzz3Zve4yeH1
Gapping up
In reaction to strong earnings/guidance: PRSC +22.1%, CALL +14.9%, REN +14.6%, CVSL +11.8%, WYY +11.8%, VRTU +9.1%, ORIG +7.8%, RGSE +7%, PLAB +6.2%, PNX +5.4%, XON +5%, NSPH +4.9%, CHRS +4.4%, PRKR +4.4%, NCMI +4.4%, SCLN +4.3%, VBLT +3.7%, ARNA +3.6%, CPRX +3.5%, PFSW +3%, USAT +2.8%, DTSI +2.7%, OPHT +2.5%, SYN +2.4%, RICK +2.3%, OVAS +2.1%, CYTX +2%, RDY +1.8%, FF +1.6%, PRTS +1.5%, LBMH +1.4%, INUV +1.4%, TCRD +1.3%, ARCO +1.3%, ELTK +1%, PFIN +1%, SCAI +0.8%, OTIV +0.7%
M&A news: PLL +20.8% (WSJ reporting that Danaher (DHR) and Thermo Fisher Scientific (TMO) may consider possible takeover of PLL), AOL +17.9% (to be acquired by Verizon (VZ) for $50 per share, or ~$4.4 bln), PRE +2.2% (Exor confirms it has increased its all-cash binding offer to acquire PartnerRe to $137.50 per Share), VZ +-0.7% (acquired by AOL for $50 per share, or ~$4.4 bln)
Select metals/mining stocks trading higher: MT +2.1%, ABX +1.6%, GOLD +1.5%, GG +1.2%, GDX +1.1%, NEM +0.9%, BHP +0.8%, SLV +0.7%, .
Other news: THLD +15.4% (Threshold Pharma and Partner Merck KGaA (MKGAY.PK) receive FDA fast track designation for Evofosfamide, to treat advanced pancreatic cancer), EOX +10.1% (entered into definitive agreement to acquire core Delaware Basin acreage in Lea and Eddy Counties, New Mexico for $75.2 mln; increases FY15 production and CapEx guidance), SPPI +8.9% (Armistice Capital discloses 5.4% stake in 13D filing, sends letter to the company requesting it initiate a complete or partial sale), OCN +7.2% (filed 2014 Form 10-K without a qualification about its ability to operate as a going concern; expects to file its first quarter Form 10-Q on or before May 18), STM +5.3% (provides investor update in Analyst Day presentations; says back to y/y revenue growth starting from 2H 2015), NAVB +4.6% secured $60 Million loan with CRG; funding to support Lymphoseek commercialization and advancement of development pipeline), ARNA +3.6% (co and Roivant Sciences enter into collaboration for nelotanserin, a novel inverse agonist of the 5-HT2A receptor; co also reported earnings), HK +3.1% (Franklin Resources disclosed 13.5% passive stake in 13G filing), CDK +2.5% (Elliott Associates disclosed 7.6% active stake in 13D filing), ZIXI +2.2% (announces share repurchase program of up to $15 mln)
Analyst comments: ANTH +2.5% (upgraded to Neutral from Sell at Citigroup), SYT +2.2% (upgraded to Mkt Perform from Underperform at Bernstein), DEG +1.6% (upgraded to Buy from Hold at Jefferies; also confirmed talks with AHONY ), EW +1.3% (upgraded to Overweight from Neutral at JP Morgan), JNPR +1% (upgraded to Buy from Neutral at BofA/Merrill)
Read more: http://www.briefing.com/Platinum/InDepth/InPlay.htm#ixzz3Zvdu88yA
Notable movers of interest
The following are some of today's most notable movers of interest, categorized by market capitalization (large cap over $10 billion and mid cap between $2-10 billion) and ranked by % change (all stocks over 100K average daily volume).
Large Cap Gainers
MNST (135.76 +5.68%): Upgraded to Buy from Neutral at Citigroup; tgt raised to $155 from $141.
ACT (302.52 +3.31%): Beat Q1 consensus EPS estimates by $0.36, beat on revs; guided FY15 EPS in-line.
CAT (89.44 +2.44%): Upgraded to Outperform from Neutral at Robert W. Baird.
Large Cap Losers
NBL (46.44 -5.47%): Announced it would acquire Rosetta Resources (ROSE) for $2.1 bln.
NOV (51.65 -2.97%): Downgraded to Sell from Neutral at Citigroup.
NTAP (34.99 -1.84%): Downgraded to Underperform from Sector Perform at Pacific Crest.
Mid Cap Gainers
CALM (50.37 +17.14%): PT raised to $67 from $51 at Sidoti.
DEG (23.17 +14.87%): Reports out suggesting Ahold (AHONY) and Delhaize could merge.
Z (98.05 +6.25%): Upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey; tgt raised to $130 from $110.
Mid Cap Losers
ETSY (20.67 -8.98%): Downgraded to Underperform from Neutral at Wedbush ; tgt $14.
CBD (31.17 -4.59%): Downgraded to Neutral at BofA/Merrill.
What’s the Day Trading Success Rate? The Thorough Answer
Wait until after market hours to read this, as it is a little lengthy, but I found it quite interesting...
http://vantagepointtrading.com/archives/13922
Yep and best of luck with them all, conix...
but hey...remember that we do not post on BB/OTC/Pinkies here...
I have been a little lax on enforcing that, but it is still our policy...
Thanks for your support...